Glucos Fresenius Kabi

Glucos Fresenius Kabi is an intravenous solution containing glucose as the active ingredient. It is supplied in a parenteral nutrition formulation without a disclosed strength, intended for intravenous administration. The product is marketed in the European Union and classified as a prescription (Rx) excipient used to provide carbohydrate energy in clinical settings.

Glucos Fresenius Kabi is employed when a rapid source of carbohydrate is required intravenously. It supports patients who cannot receive oral nutrition and helps maintain fluid and electrolyte balance.

- Treatment of hypoglycemia in acute care settings - Component of total parenteral nutrition (TPN) regimens - Fluid and electrolyte replacement during surgery or trauma - Support for critically ill patients requiring energy supplementation - Nutritional support for neonates and infants when enteral feeding is not possible

Side effects of intravenous glucose solutions can vary in frequency and severity.

Common: - Hyperglycemia (elevated blood glucose levels) - Local irritation or phlebitis at the infusion site - Electrolyte disturbances, such as hyponatremia - Fluid overload, especially in patients with cardiac or renal impairment

Serious: - Severe hyperglycemia leading to diabetic ketoacidosis - Allergic reaction or anaphylaxis (rare) - Severe electrolyte imbalance causing cardiac arrhythmia - Pulmonary edema due to rapid volume expansion

Clinicians should assess patient-specific factors before administering Glucos Fresenius Kabi. Proper monitoring and dosage adjustments are essential to minimize risks.

- Verify blood glucose levels prior to infusion and monitor during therapy - Adjust infusion rate in patients with renal or cardiac failure to avoid fluid overload - Use caution in diabetic patients or those with impaired glucose tolerance - Ensure compatibility with other intravenous solutions to prevent precipitation - Observe for signs of infection at the catheter site - Document any adverse reactions promptly

Glucose solutions may interact with other medications or clinical conditions, influencing safety and efficacy.

Avoid: - Co-administration with high-dose insulin without appropriate monitoring, which can cause severe hypoglycemia - Simultaneous infusion of calcium-containing solutions that may precipitate with phosphate

Use with caution: - Concurrent use of diuretics, which may exacerbate electrolyte shifts - Administration alongside beta‑adrenergic agonists that can increase blood glucose levels - Use in patients receiving corticosteroids, which may raise glucose concentrations - Combination with other hypertonic solutions, requiring careful volume management